115 related articles for article (PubMed ID: 37668363)
1. Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.
Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
Ito C; Nishizuka SS; Ishida K; Uesugi N; Sugai T; Tamura G; Koeda K; Sasaki A
J Surg Res; 2017 May; 212():195-204. PubMed ID: 28550907
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
11. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation.
Bertelsen BI; Steine SJ; Sandvei R; Molven A; Laerum OD
Int J Cancer; 2006 Apr; 118(8):1877-83. PubMed ID: 16287065
[TBL] [Abstract][Full Text] [Related]
13. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
16. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
[TBL] [Abstract][Full Text] [Related]
19. High incidence of PI3K pathway gene mutations in South Indian cervical cancers.
Rose MM; Dhamodharan S; Revathidevi S; Chakkarappan SR; Jagadeesan MG; Subbiah S; Nakaoka H; Inoue I; Murugan AK; Munirajan AK
Cancer Genet; 2022 Jun; 264-265():100-108. PubMed ID: 35568000
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]